BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-767. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 115] [Article Influence: 23.7] [Reference Citation Analysis]
Number Citing Articles
1 Kawami N, Takenouchi N, Umezawa M, Hoshino S, Hanada Y, Hoshikawa Y, Sano H, Hoshihara Y, Nomura T, Uchida E, Iwakiri K. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of <b><i>Helicobacter pylori </i></b>Infection. Digestion 2017;95:140-5. [DOI: 10.1159/000455834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Ohnishi S, Watari H, Kanno M, Ohba Y, Takeuchi S, Miyaji T, Oyamada S, Nomura E, Kato H, Sugiyama T, Asaka M, Sakuragi N, Yamaguchi T, Uezono Y, Iwase S. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). J Gynecol Oncol 2017;28:e44. [PMID: 28657216 DOI: 10.3802/jgo.2017.28.e44] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
3 Sakurai K, Suda H, Fujie S, Takeichi T, Okuda A, Murao T, Hasuda K, Hirano M, Ito K, Tsuruta K, Hattori M. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan. Dig Dis Sci 2019;64:815-22. [PMID: 30415407 DOI: 10.1007/s10620-018-5365-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Zhang MY, Tan ND, Li YW, Sifrim D, Pandolfino JE, Xiao YL, Chen MH. Esophageal symptoms versus epigastric symptoms: Relevance for diagnosis of gastroesophageal reflux disease. J Dig Dis 2020;21:696-704. [PMID: 32975045 DOI: 10.1111/1751-2980.12946] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Qiu B, Zhang X, Bai T, Xu J, Xiang X, Hou X. The importance of pH reflux monitoring test for the management of low-grade esophagitis in Chinese patients. Neurogastroenterol Motil 2019;31:e13653. [PMID: 31157483 DOI: 10.1111/nmo.13653] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Fukahori S, Yagi M, Kawahara H, Masui D, Hashizume N, Taguchi T. Current status of intractable pediatric gastroesophageal reflux disease in Japan: a nationwide survey. Surg Today 2022. [PMID: 34982227 DOI: 10.1007/s00595-021-02444-w] [Reference Citation Analysis]
7 Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, Sheu BS, Chong CF, Funao N, Zhou W, Chen M. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 2020;69:224-30. [PMID: 31409606 DOI: 10.1136/gutjnl-2019-318365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
8 Zhang J, Che H, Zhang B, Zhang C, Zhou B, Ji H, Xie J, Shi X, Li X, Wang F, Tang X. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study. Phytomedicine 2021;88:153584. [PMID: 34119741 DOI: 10.1016/j.phymed.2021.153584] [Reference Citation Analysis]
9 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
10 Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis. Medicine (Baltimore) 2018;97:e12574. [PMID: 30278564 DOI: 10.1097/MD.0000000000012574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
11 Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Kobayashi Y, Lefor AK, Yamamoto H. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep 2017;7:231-5. [PMID: 28894571 DOI: 10.3892/br.2017.947] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
12 Dowgiałło-Wnukiewicz N, Frask A, Lech P, Michalik M. Study of the prevalence of gastroesophageal reflux symptoms and the role of each in relation to the GERD Impact Scale, based on a population of patients admitted for laparoscopic surgery compared to a control group. Wideochir Inne Tech Maloinwazyjne 2018;13:199-211. [PMID: 30002752 DOI: 10.5114/wiitm.2018.75909] [Reference Citation Analysis]
13 Sumi S, Ishimura N, Mikami H, Okimoto E, Tamagawa Y, Mishiro T, Kinoshita Y, Ishihara S. Evaluations of Gastric Acid Pocket Using Novel Vertical 8-Channel pH Monitoring System and Effects of Acid Secretion Inhibitors. J Neurogastroenterol Motil 2021;27:370-6. [PMID: 34210902 DOI: 10.5056/jnm20115] [Reference Citation Analysis]
14 Fujiwara Y. Symptom-based diagnostic approach for eosinophilic esophagitis. J Gastroenterol 2020;55:833-45. [PMID: 32720208 DOI: 10.1007/s00535-020-01701-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Imagama S, Ando K, Kobayashi K, Machino M, Tanaka S, Morozumi M, Kanbara S, Ito S, Seki T, Hamada T, Ishizuka S, Nakashima H, Ishiguro N, Hasegawa Y. Increase in lumbar kyphosis and spinal inclination, declining back muscle strength, and sarcopenia are risk factors for onset of GERD: a 5-year prospective longitudinal cohort study. Eur Spine J 2019;28:2619-28. [PMID: 31506765 DOI: 10.1007/s00586-019-06139-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
16 Köckerling F, Trommer Y, Zarras K, Adolf D, Kraft B, Weyhe D, Fortelny R, Schug-Paß C. What are the differences in the outcome of laparoscopic axial (I) versus paraesophageal (II-IV) hiatal hernia repair? Surg Endosc 2017;31:5327-41. [PMID: 28597286 DOI: 10.1007/s00464-017-5612-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kung Y, Hsu W, Wu M, Wang J, Liu C, Su Y, Kuo C, Kuo F, Wu D, Wang Y. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci 2017;62:3298-316. [DOI: 10.1007/s10620-017-4830-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
18 Wei CY, Tzeng IS, Lin MC, Yeh YH, Hsu CY, Kung WM. Risks of Sulpiride-Induced Parkinsonism in Peptic Ulcer and Gastroesophageal Reflux Disease Patients in Taiwan: A Nationwide Population-Based Study. Front Pharmacol 2020;11:433. [PMID: 32390831 DOI: 10.3389/fphar.2020.00433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Bang CS, Yang YJ, Baik GH. Melatonin for the treatment of gastroesophageal reflux disease; protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14241. [PMID: 30681611 DOI: 10.1097/md.0000000000014241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
20 Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, Kojima Y, Sakamoto H, Kuramoto T, Kojima K, Sanomura M, Hoshimoto M, Higashino T, Itabashi T, Takada K, Sakaguchi M, Tominaga K, Kusano M, Higuchi K. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol 2018;33:623-30. [PMID: 28865098 DOI: 10.1111/jgh.13970] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
21 Kaniecki T, Abdi T, McMahan ZH. A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. Best Pract Res Clin Rheumatol 2021;:101666. [PMID: 33676855 DOI: 10.1016/j.berh.2021.101666] [Reference Citation Analysis]
22 Yoon S, Oh E, Park MS, Jang SB, Byun HM, Park H, Kim H, Kim CO. Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen. Transl Clin Pharmacol 2021;29:150-9. [PMID: 34621707 DOI: 10.12793/tcp.2021.29.e15] [Reference Citation Analysis]
23 Kim SY, Jung H, Lee HA. Normal acid exposure time in esophageal pH monitoring in Asian and Western populations: A systematic review and meta‐analysis. Neurogastroenterology & Motility 2021;33. [DOI: 10.1111/nmo.14029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kikuchi H, Fukuda S, Koike T, Shimodaira Y, Watanabe K, Saito M, Nakagawa K, Hatta W, Masamune A, Iijima K. Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy. Esophagus 2021;18:380-7. [PMID: 32737802 DOI: 10.1007/s10388-020-00765-2] [Reference Citation Analysis]
25 Morimoto C, Matsumoto H, Nagasaki T, Kanemitsu Y, Ishiyama Y, Sunadome H, Oguma T, Ito I, Murase K, Kawaguchi T, Tabara Y, Niimi A, Muro S, Matsuda F, Chin K, Hirai T. Gastroesophageal reflux disease is a risk factor for sputum production in the general population: the Nagahama study. Respir Res 2021;22:6. [PMID: 33407482 DOI: 10.1186/s12931-020-01601-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kellerman R, Kintanar T. Gastroesophageal Reflux Disease. Prim Care. 2017;44:561-573. [PMID: 29132520 DOI: 10.1016/j.pop.2017.07.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
27 Park CH, Lee SK. [Gastroesophageal Reflux Disease]. Korean J Gastroenterol 2019;73:70-6. [PMID: 30845382 DOI: 10.4166/kjg.2019.73.2.70] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Xiao YL, Zhou LY, Hou XH, Li YQ, Zou DW, Chen MH; Chinese Society of Gastroenterology. Chinese expert consensus on gastroesophageal reflux disease in 2020. J Dig Dis 2021;22:376-89. [PMID: 34105263 DOI: 10.1111/1751-2980.13028] [Reference Citation Analysis]
29 Zhang H, Gao W, Wang L, Suzhen, Gao Y, Liu B, Zhou H, Fang D. A population-based study on prevalence and risk factors of gastroesophageal reflux disease in the Tibet Autonomous Region, China. PeerJ 2019;7:e6491. [PMID: 30842901 DOI: 10.7717/peerj.6491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Nicolau CA, Prorock A, Bao Y, Neves-Ferreira AGDC, Valente RH, Fox JW. Revisiting the Therapeutic Potential of Bothrops jararaca Venom: Screening for Novel Activities Using Connectivity Mapping. Toxins (Basel) 2018;10:E69. [PMID: 29415440 DOI: 10.3390/toxins10020069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Hanada Y, Hoshino S, Hoshikawa Y, Takenouchi N, Umezawa M, Kawami N, Iwakiri K. Endoscopic diagnosis of hiatus hernia under deep inspiration is not consistent with esophageal manometric diagnosis. J Gastroenterol 2018;53:712-7. [PMID: 29075901 DOI: 10.1007/s00535-017-1403-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
32 Kasamatsu S, Matsumura T, Ohta Y, Hamanaka S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Nakagawa T, Katsuno T, Fujie M, Kikuchi A, Arai M. The Effect of Ineffective Esophageal Motility on Gastroesophageal Reflux Disease. Digestion 2017;95:221-8. [PMID: 28343226 DOI: 10.1159/000468925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
33 Shinozaki S, Osawa H, Hayashi Y, Miura Y, Lefor AK, Yamamoto H. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep 2021;14:32. [PMID: 33585034 DOI: 10.3892/br.2021.1408] [Reference Citation Analysis]
34 Monczor F, Fernandez N. Current Knowledge and Perspectives on Histamine H1 and H2 Receptor Pharmacology: Functional Selectivity, Receptor Crosstalk, and Repositioning of Classic Histaminergic Ligands. Mol Pharmacol 2016;90:640-8. [PMID: 27625037 DOI: 10.1124/mol.116.105981] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
35 Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol 2018;53:834-44. [PMID: 29188387 DOI: 10.1007/s00535-017-1417-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
36 Hoshino N, Nishizaki D, Hida K, Obama K, Sakai Y. Rikkunshito for upper gastrointestinal symptoms: A systematic review and meta-analysis. Complement Ther Med 2019;42:255-63. [PMID: 30670250 DOI: 10.1016/j.ctim.2018.11.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Yun JS, Na KJ, Song SY, Kim S, Kim E, Jeong IS, Oh SG. Laparoscopic repair of hiatal hernia. J Thorac Dis 2019;11:3903-8. [PMID: 31656664 DOI: 10.21037/jtd.2019.08.94] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Momma E, Koeda M, Tanabe T, Hoshikawa Y, Hoshino S, Kawami N, Kawagoe T, Tatsuguchi A, Kaise M, Iwakiri K. Relationship between gastroesophageal reflux disease (GERD) and constipation: laxative use is common in GERD patients. Esophagus 2021;18:152-5. [PMID: 32860581 DOI: 10.1007/s10388-020-00770-5] [Reference Citation Analysis]
39 Liu ZZ, Ren Q, Zhou YN, Yang HM. Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects. World J Clin Cases 2020; 8(22): 5518-5528 [PMID: 33344542 DOI: 10.12998/wjcc.v8.i22.5518] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Mori H, Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019;25:6-14. [PMID: 30504527 DOI: 10.5056/jnm18139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
41 Kawami N, Hoshino S, Hoshikawa Y, Takenouchi N, Umezawa M, Hanada Y, Kaise M, Iwakiri K. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease. Digestion 2018;98:194-200. [DOI: 10.1159/000488530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Schmulson MJ, Frati-Munari AC. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Rev Gastroenterol Mex. 2019;84:44-51. [PMID: 29678362 DOI: 10.1016/j.rgmx.2018.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
43 Kato M, Ito N, Demura M, Kubo K, Mabe K, Harada N. Study for every other day administration of vonoprazan in maintenance treatment of erosive GERD: study protocol for a multicentre randomised cross-over study. BMJ Open Gastroenterol 2018;5:e000197. [PMID: 29527318 DOI: 10.1136/bmjgast-2017-000197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Cho JH, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study. Medicine (Baltimore) 2020;99:e22729. [PMID: 33126310 DOI: 10.1097/MD.0000000000022729] [Reference Citation Analysis]
45 Okuyama M, Nakahara K, Iwakura N, Hasegawa T, Oyama M, Inoue A, Ishizu H, Satoh H, Fujiwara Y. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Digestion 2017;95:281-7. [PMID: 28501868 DOI: 10.1159/000475658] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
46 Wang CC, Chiu YC, Chen WL, Yang TW, Tsai MC, Tseng MH. A Deep Learning Model for Classification of Endoscopic Gastroesophageal Reflux Disease. Int J Environ Res Public Health 2021;18:2428. [PMID: 33801325 DOI: 10.3390/ijerph18052428] [Reference Citation Analysis]
47 Aoyama K, Kunieda K, Shigematsu T, Ohno T, Fujishima I. Effect of Bridge Position Swallow on Esophageal Motility in Healthy Individuals Using High-Resolution Manometry. Dysphagia 2021;36:551-7. [PMID: 32749546 DOI: 10.1007/s00455-020-10169-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Xi L, Zhu J, Zhang H, Muktiali M, Li Y, Wu A. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. Esophagus 2021;18:144-51. [PMID: 32519226 DOI: 10.1007/s10388-020-00753-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Kinoshita Y, Kusano M, Iwakiri K, Fujishiro M, Tachikawa N, Haruma K. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. Curr Ther Res Clin Exp 2018;88:26-34. [PMID: 30038671 DOI: 10.1016/j.curtheres.2018.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 AlMutairi H, O'Dwyer M, McCarron M, McCallion P, Henman MC. The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study. Saudi Pharm J 2018;26:1012-21. [PMID: 30416357 DOI: 10.1016/j.jsps.2018.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract 2018;7:41-52. [PMID: 29892570 DOI: 10.2147/IPRP.S142932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
53 Franceschelli S, Gatta DMP, Pesce M, Ferrone A, Di Martino G, Di Nicola M, De Lutiis MA, Vitacolonna E, Patruno A, Grilli A, Felaco M, Speranza L. Modulation of the oxidative plasmatic state in gastroesophageal reflux disease with the addition of rich water molecular hydrogen: A new biological vision. J Cell Mol Med 2018;22:2750-9. [PMID: 29512923 DOI: 10.1111/jcmm.13569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
54 Abdi S, Sargashteh Z, Abbasinazari M, Salamzadeh J, Mortazavi SA. Buccal Buspirone as add-on Therapy to Omeprazole Versus Omeprazole in Treatment of Gastroesophageal Reflux Diseases (GERD). Iran J Pharm Res 2020;19:113-20. [PMID: 33841527 DOI: 10.22037/ijpr.2020.113320.14231] [Reference Citation Analysis]
55 Okanobu H, Kohno T, Mouri R, Hatsushika Y, Yamashita Y, Miyaki E, Fukuhara T, Okazaki A, Sakano A, Urabe A, Takaki S, Mori N, Tsuji K, Ochi H, Furukawa Y. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study. Esophagus 2021;18:669-75. [PMID: 33221955 DOI: 10.1007/s10388-020-00798-7] [Reference Citation Analysis]
56 Slater BJ, Dirks RC, McKinley SK, Ansari MT, Kohn GP, Thosani N, Qumseya B, Billmeier S, Daly S, Crawford C, P Ehlers A, Hollands C, Palazzo F, Rodriguez N, Train A, Wassenaar E, Walsh D, Pryor AD, Stefanidis D. SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD). Surg Endosc 2021;35:4903-17. [PMID: 34279710 DOI: 10.1007/s00464-021-08625-5] [Reference Citation Analysis]
57 Takahashi S, Matsumura T, Kaneko T, Tokunaga M, Oura H, Ishikawa T, Nagashima A, Shiratori W, Akizue N, Ohta Y, Kikuchi A, Fujie M, Saito K, Okimoto K, Maruoka D, Nakagawa T, Arai M, Kato J, Kato N. Clinical Characteristics of Esophageal Motility Disorders in Patients With Heartburn. J Neurogastroenterol Motil 2021;27:545-54. [PMID: 34642275 DOI: 10.5056/jnm20131] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Fukahori S, Yagi M, Ishii S, Asagiri K, Saikusa N, Hashizume N, Yoshida M, Masui D, Komatsuzaki N, Higashidate N, Nakahara H, Tanaka Y. A baseline impedance analysis in neurologically impaired children: A potent parameter for estimating the condition of the esophageal mucosa. Neurogastroenterol Motil 2017;29. [PMID: 28086260 DOI: 10.1111/nmo.13012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
59 Ohashi S, Maruno T, Fukuyama K, Kikuchi O, Sunami T, Kondo Y, Imai S, Matsushima A, Suzuki K, Usui F, Yakami M, Yamada A, Isoda H, Matsumoto S, Seno H, Muto M, Inoue M. Visceral fat obesity is the key risk factor for the development of reflux erosive esophagitis in 40-69-years subjects. Esophagus 2021;18:889-99. [PMID: 34117973 DOI: 10.1007/s10388-021-00859-5] [Reference Citation Analysis]
60 Villamil Morales IM, Gallego Ospina DM, Otero Regino WA. Impact of head of bed elevation in symptoms of patients with gastroesophageal reflux disease: a randomized single-blind study (IBELGA). Gastroenterol Hepatol 2020;43:310-21. [PMID: 32229033 DOI: 10.1016/j.gastrohep.2020.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Park HJ, Park YM, Kim JH, Lee HS, Kim HJ, Ahn CM, Byun MK. Effectiveness of proton pump inhibitor in unexplained chronic cough. PLoS One 2017;12:e0185397. [PMID: 29016626 DOI: 10.1371/journal.pone.0185397] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
62 Nakayama Y, Ida S. Endoscopic findings of esophagogastric junction in children. Dig Endosc 2017;29 Suppl 2:11-7. [PMID: 28425652 DOI: 10.1111/den.12793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, Iwakiri K, Ashida K. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study. Clin Transl Gastroenterol 2019;10:e00101. [PMID: 31770139 DOI: 10.14309/ctg.0000000000000101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
64 Nam SY, Park BJ, Cho Y, Ryu KH, Choi IJ, Park S, Kim Y. Different effects of dietary factors on reflux esophagitis and non-erosive reflux disease in 11,690 Korean subjects. J Gastroenterol 2017;52:818-29. [DOI: 10.1007/s00535-016-1282-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
65 Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2020;8:CD013113. [PMID: 32844430 DOI: 10.1002/14651858.CD013113.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Mukaisho KI, Kanai S, Kushima R, Nakayama T, Hattori T, Sugihara H. Barretts's carcinogenesis. Pathol Int 2019;69:319-30. [PMID: 31290583 DOI: 10.1111/pin.12804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
67 Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, Watari J, Miwa H. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019;49:140-6. [DOI: 10.1111/apt.15062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
68 Nam SY, Park BJ, Cho YA, Ryu KH. Gender-specific Effect of Micronutrient on Non-erosive Reflux Disease and Erosive Esophagitis. J Neurogastroenterol Motil 2019;25:82-90. [PMID: 30646479 DOI: 10.5056/jnm18114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Tan J, Li L, Huang X, Yang C, Liang X, Zhao Y, Xie J, Chen R, Wang D, Xie S. Associations between gastro-oesophageal reflux disease and a range of diseases: an umbrella review of systematic reviews and meta-analyses. BMJ Open 2020;10:e038450. [PMID: 33380477 DOI: 10.1136/bmjopen-2020-038450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Shinozaki S, Osawa H, Hayashi Y, Miura Y, Yano T, Lefor AK, Yamamoto H. Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Helicobactor pylori eradication therapy. Scand J Gastroenterol 2021;:1-6. [PMID: 34547219 DOI: 10.1080/00365521.2021.1975310] [Reference Citation Analysis]
71 Dragomiretska NV, Babov KD, Gushcha SG, Zabolotna IB, Plakida AL, Izha AN, Babova IK, Nasibullin BA, Trubka IA. Application of mineral waters in the complex treatment of patients with gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2020;66:225-37. [PMID: 32218417 DOI: 10.23736/S1121-421X.20.02601-X] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Jung DH, Huh CW, Lee SK, Park JC, Shin SK, Lee YC. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:165-75. [PMID: 33795539 DOI: 10.5056/jnm20161] [Reference Citation Analysis]
73 Bert F, Pompili E, Lo Moro G, Corradi A, Sagrawa Caro A, Gualano MR, Siliquini R. Prevalence of gastro-oesophageal reflux symptoms: An Italian cross-sectional survey focusing on knowledge and attitudes towards lifestyle and nutrition. Int J Clin Pract. 2021;75:e13758. [PMID: 33098613 DOI: 10.1111/ijcp.13758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Perivoliotis K, Sarakatsianou C, Tepetes K, Baloyiannis I. Single incision laparoscopic fundoplication: A systematic review of the literature. World J Gastrointest Surg 2019; 11(3): 179-190 [PMID: 31057702 DOI: 10.4240/wjgs.v11.i3.179] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. The Journal of Clinical Pharmacology 2018;58:425-33. [DOI: 10.1002/jcph.1038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
76 Ye X, Wang X, Wang Y, Sun W, Chen Y, Wang D, Li Z, Li Z. A urine and serum metabolomics study of gastroesophageal reflux disease in TCM syndrome differentiation using UPLC-Q-TOF/MS. J Pharm Biomed Anal 2021;206:114369. [PMID: 34551376 DOI: 10.1016/j.jpba.2021.114369] [Reference Citation Analysis]
77 Fujimoto S, Tsuruoka N, Esaki M, Takamori A, Sakata Y, Shimoda R, Akutagawa T, Node K, Anzai K, Sugisaki N, Iwakiri R, Takagi K, Yamanouchi K, Fujimoto K. Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients. J Clin Biochem Nutr 2021;68:95-100. [PMID: 33536718 DOI: 10.3164/jcbn.20-153] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Maev IV, Andreev DN, Kucheryavyy YA, Shaburov RI. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii arkhiv 2019;91:4-11. [DOI: 10.26442/00403660.2019.08.000387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Dao HV, Matsumura T, Kaneko T, Takahashi S, Tokunaga M, Oura H, Ishikawa K, Akizue N, Kikuchi A, Fujie M, Saito K, Okimoto K, Maruoka D, Nakagawa T, Arai M, Kato J, Kato N. Impact of ineffective esophageal motility on chemical clearance in patients with gastroesophageal reflux symptoms. Dis Esophagus 2020;33:doaa026. [PMID: 32409817 DOI: 10.1093/dote/doaa026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
80 Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018;24:334-344. [PMID: 29739175 DOI: 10.5056/jnm18029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
81 Habu Y, Hamasaki R, Maruo M, Nakagawa T, Aono Y, Hachimine D. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan. J Gen Fam Med 2021;22:237-45. [PMID: 34484992 DOI: 10.1002/jgf2.429] [Reference Citation Analysis]
82 Shinozaki S, Osawa H, Kobayashi Y, Sakamoto H, Hayashi Y, Miura Y, Kawarai Lefor A, Yamamoto H. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan. Scand J Gastroenterol 2018;53:897-904. [PMID: 30056768 DOI: 10.1080/00365521.2018.1486883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Bazelle J, Threlfall A, Whitley N. Gastroprotectants in small animal veterinary practice - a review of the evidence. Part 1: cyto-protective drugs. J Small Anim Pract 2018. [PMID: 29974466 DOI: 10.1111/jsap.12867] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Kusakari M, Nakayama Y, Horiuchi A, Nakazawa Y. Trends in gastroesophageal reflux disease in Japanese children and adolescents. Pediatr Int 2020;62:1269-74. [PMID: 32473087 DOI: 10.1111/ped.14324] [Reference Citation Analysis]
85 Niikura R, Yamada A, Hirata Y, Hayakawa Y, Takahashi A, Shinozaki T, Takeuchi Y, Fujishiro M, Koike K. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease. Intern Med 2018;57:2443-50. [PMID: 29607951 DOI: 10.2169/internalmedicine.0492-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
86 Kaniecki T, Abdi T, McMahan ZH. Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis. Med Res Arch 2020;8:2252. [PMID: 34337149 DOI: 10.18103/mra.v8i10.2252] [Reference Citation Analysis]
87 Marques de Sá I, Pereira AD, Sharma P, Dinis-Ribeiro M. Systematic review of the published guidelines on Barrett's esophagus: should we stress the consensus or the differences? Dis Esophagus 2020:doaa115. [PMID: 33249488 DOI: 10.1093/dote/doaa115] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Seo HS, Choi M, Son SY, Kim MG, Han DS, Lee HH. Evidence-Based Practice Guideline for Surgical Treatment of Gastroesophageal Reflux Disease 2018. J Gastric Cancer. 2018;18:313-327. [PMID: 30607295 DOI: 10.5230/jgc.2018.18.e41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
90 Miftahussurur M, Doohan D, Nusi IA, Adi P, Rezkitha YAA, Waskito LA, Fauzia KA, Bramantoro T, Maimunah U, Thamrin H, Masithah SI, Sukadiono S, Uchida T, Lusida MI, Yamaoka Y. Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PLoS One 2018;13:e0205644. [PMID: 30427843 DOI: 10.1371/journal.pone.0205644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
91 Kang HJ, Jeong MK, Park SJ, Jun HJ, Yoo HS. Efficacy and safety of Yukgunja-Tang for treating anorexia in patients with cancer: The protocol for a pilot, randomized, controlled trial. Medicine (Baltimore) 2019;98:e16950. [PMID: 31577697 DOI: 10.1097/MD.0000000000016950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
92 Isshi K, Matsuhashi N, Joh T, Higuchi K, Iwakiri K, Kamiya T, Manabe N, Ogawa M, Arihiro S, Haruma K, Nakada K. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol 2019;54:492-500. [DOI: 10.1007/s00535-019-01546-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
93 Takedomi H, Tsuruoka N, Takamori A, Miyahara K, Yamanouchi K, Shimamura T, Fujimoto Y, Noda T, Matsunaga T, Takara Y, Shimada F, Hidaka H, Endo H, Anzai K, Fujimoto K. Correlation of Barrett's esophagus with colorectal polyps in Japanese patients: A retrospective chart review. J Gastroenterol Hepatol 2019;34:1160-5. [PMID: 30667560 DOI: 10.1111/jgh.14610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Yu SY, Lee B, McGuire TM, Lee HJ, Hollingworth SA. Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. Eur J Clin Pharmacol 2020;76:547-55. [PMID: 31822956 DOI: 10.1007/s00228-019-02798-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
95 Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021;22:219-27. [PMID: 32893683 DOI: 10.1080/14656566.2020.1817385] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology 2021. [PMID: 34018229 DOI: 10.1002/hep.31914] [Reference Citation Analysis]
97 Nahata M, Mizuhara Y, Sadakane C, Watanabe J, Fujitsuka N, Hattori T. Influence of food on the gastric motor effect of the Kampo medicine rikkunshito in rat. Neurogastroenterol Motil 2018;30. [PMID: 28776825 DOI: 10.1111/nmo.13177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
98 Yokoya Y, Igarashi A, Uda A, Deguchi H, Takeuchi T, Higuchi K. Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD. J Gastroenterol 2019;54:1083-95. [DOI: 10.1007/s00535-019-01609-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
99 Oda M, Kalloo A, Mizukami K, Murakami K, Sawa A. Endoscopy and Barrett's Esophagus: Current Perspectives in the US and Japan. Intern Med 2021;60:327-35. [PMID: 32863360 DOI: 10.2169/internalmedicine.4400-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Umezawa M, Kawami N, Hoshino S, Hoshikawa Y, Koizumi E, Takenouchi N, Hanada Y, Kaise M, Iwakiri K. Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis. Digestion 2018;97:309-15. [PMID: 29514137 DOI: 10.1159/000485795] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
101 Shibli F, Skeans J, Yamasaki T, Fass R. Nocturnal Gastroesophageal Reflux Disease (GERD) and Sleep: An Important Relationship That Is Commonly Overlooked. Journal of Clinical Gastroenterology 2020;54:663-74. [DOI: 10.1097/mcg.0000000000001382] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
102 Mochizuki N, Fujita T, Kobayashi M, Yamazaki Y, Terao S, Sanuki T, Okada A, Adachi M, Murakami M, Arisaka Y, Uno K, Masuda A, Yoshida M, Umegaki E, Kutsumi H, Azuma T. Factors associated with the presentation of erosive esophagitis symptoms in health checkup subjects: A prospective, multicenter cohort study. PLoS One 2018;13:e0196848. [PMID: 29723303 DOI: 10.1371/journal.pone.0196848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
103 Wu Y, Wang J, Huang Q, Peng T, Zhao L, Feng G, Liu Y. The Relationship Between Gastroesophageal Reflux Disease and Laryngopharyngeal Reflux Based on pH Monitoring. Ear Nose Throat J 2021;100:249-53. [PMID: 33170043 DOI: 10.1177/0145561320971915] [Reference Citation Analysis]
104 Delpiano L, Thomas JJ, Yates AR, Rice SJ, Gray MA, Saint-Criq V. Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells. Front Pharmacol 2018;9:1462. [PMID: 30618754 DOI: 10.3389/fphar.2018.01462] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
105 Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, Iwakiri K. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion. 2017;95:156-161. [PMID: 28190016 DOI: 10.1159/000456072] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 9.6] [Reference Citation Analysis]
106 Jiang X, Zhang F, Li Y, Ren J, Xu D, Cai R, Yi Z, Li C, Liu T, Zhang X, Yao H, Zhu T, Mu R. Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis. Rheumatology (Oxford) 2021:keab724. [PMID: 34599809 DOI: 10.1093/rheumatology/keab724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Jung HK, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Miwa H, Chen CL, Gonlachanvit S, Ghoshal UC, Wu JCY, Siah KTH, Hou X, Oshima T, Choi MY, Lee KJ; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-81. [PMID: 34642267 DOI: 10.5056/jnm21077] [Reference Citation Analysis]
108 Bongiovanni A, Manti S, Parisi GF, Papale M, Mulè E, Rotolo N, Leonardi S. Focus on gastroesophageal reflux disease in patients with cystic fibrosis. World J Gastroenterol 2020; 26(41): 6322-6334 [PMID: 33244195 DOI: 10.3748/wjg.v26.i41.6322] [Reference Citation Analysis]
109 Masaoka T, Kameyama H, Yamane T, Yamamoto Y, Takeuchi H, Suzuki H, Kitagawa Y, Kanai T. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test. J Neurogastroenterol Motil 2018;24:577-83. [PMID: 30347936 DOI: 10.5056/jnm18036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
110 Yoshioka T, Takeshita E, Sakata Y, Hara M, Akutagawa K, Sakata N, Endo H, Ohyama T, Matsunaga K, Tanaka Y, Shirai S, Ito Y, Tsuruoka N, Iwakiri R, Kusano M, Fujimoto K. Helicobacter pylori infection status had no influence on upper gastrointestinal symptoms: a cross-sectional analysis of 3,005 Japanese subjects without upper gastrointestinal lesions undergoing medical health checkups. Esophagus 2017;14:249-53. [PMID: 28725170 DOI: 10.1007/s10388-017-0573-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
111 Takeuchi T, Hongo H, Kimura T, Kojima Y, Harada S, Ota K, Takeuchi N, Noguchi T, Inoue T, Murano M, Higuchi K. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors: Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. J Gastroenterol 2019;54:972-83. [DOI: 10.1007/s00535-019-01588-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
112 Kinoshita Y, Hongo M, Kusano M, Furuhata Y, Miyagishi H, Ikeuchi S; RPZ Study Group. Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study. Intern Med. 2017;56:1131-1139. [PMID: 28502925 DOI: 10.2169/internalmedicine.56.7896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
113 Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion. 2018;97:195-204. [PMID: 29316555 DOI: 10.1159/000481813] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
114 Peters Y, Al-kaabi A, Shaheen NJ, Chak A, Blum A, Souza RF, Di Pietro M, Iyer PG, Pech O, Fitzgerald RC, Siersema PD. Barrett oesophagus. Nat Rev Dis Primers 2019;5. [DOI: 10.1038/s41572-019-0086-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
115 Hojo M, Ueda K, Takeda T, Akazawa Y, Ueyama H, Shimada Y, Asaoka D, Nagahara A. The relationship between Helicobacter pylori infection and reflux esophagitis and the long-term effects of eradication of Helicobacter pylori on reflux esophagitis. Therap Adv Gastroenterol 2021;14:17562848211059942. [PMID: 34917172 DOI: 10.1177/17562848211059942] [Reference Citation Analysis]
116 Souza RF. Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia. J Gastroenterol. 2017;52:767-776. [PMID: 28451845 DOI: 10.1007/s00535-017-1342-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
117 Koeda M, Tanabe T, Kitasako Y, Momma E, Hoshikawa Y, Hoshino S, Kawami N, Kaise M, Iwakiri K. Saliva secretion is reduced in mild reflux esophagitis patients. Esophagus 2021. [PMID: 34536162 DOI: 10.1007/s10388-021-00880-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Ban H, Inatomi O, Murata M, Otsuka T, Oi M, Matsumoto H, Bamba S, Andoh A. Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study. J Clin Biochem Nutr 2021;68:259-63. [PMID: 34025030 DOI: 10.3164/jcbn.20-143] [Reference Citation Analysis]
119 Tanabe T, Koeda M, Kitasako Y, Momma E, Hoshikawa Y, Hoshino S, Kawami N, Kaise M, Iwakiri K. Stimulated saliva secretion is reduced in proton pump inhibitor-resistant severe reflux esophagitis patients. Esophagus 2021;18:676-83. [PMID: 33590389 DOI: 10.1007/s10388-021-00825-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Clin Exp Gastroenterol 2018;11:51-6. [PMID: 29416369 DOI: 10.2147/CEG.S144149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Ko MH, Song SY, Ha SJ, Lee JY, Yoon SW, Park JH, Park SJ, Yoo HS. Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study. Integr Cancer Ther 2021;20:15347354211019107. [PMID: 34032151 DOI: 10.1177/15347354211019107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zhou Z, Kalatskaya I, Russell D, Marcon N, Cirocco M, Krzyzanowski PM, Streutker C, Liang H, Litle VR, Godfrey TE, Stein L. Combined EsophaCap cytology and MUC2 immunohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma. Clin Exp Gastroenterol 2019;12:219-29. [PMID: 31190949 DOI: 10.2147/CEG.S186958] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
123 Hoshikawa Y, Kawami N, Hoshino S, Tanabe T, Umezawa M, Kaise M, Iwakiri K. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus 2019;16:201-6. [PMID: 30600486 DOI: 10.1007/s10388-018-00654-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
124 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
125 Tanaka Y, Sakata Y, Hara M, Kawakubo H, Tsuruoka N, Yamamoto K, Itoh Y, Hidaka H, Shimoda R, Iwakiri R, Fujimoto K. Risk Factors for Helicobacter pylori Infection and Endoscopic Reflux Esophagitis in Healthy Young Japanese Volunteers. Intern Med 2017;56:2979-83. [PMID: 28943553 DOI: 10.2169/internalmedicine.8669-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
126 Funaki Y, Ogasawara N, Kawamura Y, Yoshimine T, Tamura Y, Izawa S, Ebi M, Sasaki M, Kasugai K. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. Neurogastroenterol Motil 2020;32:e13749. [PMID: 31612597 DOI: 10.1111/nmo.13749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Habu Y. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. Intern Med 2019;58:2427-33. [PMID: 31178490 DOI: 10.2169/internalmedicine.2535-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
128 Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Miura Y, Lefor AK, Yamamoto H. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. Kaohsiung J Med Sci. 2017;33:616-622. [PMID: 29132551 DOI: 10.1016/j.kjms.2017.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
129 Suhara H, Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Nakamura M, Miyahara R, Ishigami M, Hashimoto S, Goto H. Transabdominal ultrasound elastography of the esophagogastric junction predicts reflux esophagitis. J Med Ultrason (2001) 2019;46:99-104. [PMID: 30043241 DOI: 10.1007/s10396-018-0890-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
130 Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. Clin Mol Allergy 2019;17:1. [PMID: 30675130 DOI: 10.1186/s12948-019-0104-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
131 Liao WM, Xu LM. Conventional treatment combined with Rehabilitation New Fluid and flupentixol and melitracen tablets for treatment of reflux esophagitis in elderly patients. Shijie Huaren Xiaohua Zazhi 2019; 27(9): 598-604 [DOI: 10.11569/wcjd.v27.i9.598] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]